MET and neoplasm: The antibodies generated fell into three categories: 1) agonist antibodies as previously reported; 2) a series of antibodies that only bind the c-MET precursor and therefore may be tumor-specific; and, 3) bivalent antibodies that induce c-MET degradation and inhibit tumor growth.